Bausch Health rises 25% on bad earnings – is this pump a trap for retail investors?

Bausch Health’s (NASDAQ: BHC) pre-market rally is causing the ears of investors to prick up as the word gets out. While the sentiment appears to be positive at the moment investors could be in for a rollercoaster at the bell. Considering the pre-market is a usually a façade for the trading day, many investors are […]

Sorrento Therapeutics soars 10% from Jim Crammer’s bullish outlook – should investors avoid shorting SRNE?

Sorento Therapeutics (NASDAQ: SRNE) is causing Wall Street to divide. Some bears are adamant that Sorrento will become a COVID-19 stock that will fade in a few months. Whereas the bulls are aggressively buying up SRNE shares as they believe the biotech has not even come close to its true value. While the overall war […]

Here’s how much a $10,000 investment in this COVID-19 vaccine company is worth now

The COVID-19 vaccine industry has seen immense investor backing with popular US listed companies such as Moderna, Pfizer and Vaxart multiplying their pre-COVID value upwards of 500%-1,000%. However, Novavax, Inc. (NASDAQ: NVAX) has surpassed it’s rivals in stock value growth, currently priced at $143.10. An investment of $10,000 in NVAX after the initial COVID-19 vaccine […]

BNGO rises 100% off COVID-19 DNA research – here’s what you need to know.

Binano Genomics (NASDAQ: BNGO) catapulted itself onto the COVID-19 stage this week, which naturally saw investors flood the market. The area that BNGO is targeting is the COVID research field. However, for most investors, the scientific jargon can make the task of understanding the company, let alone investing, extremely difficult. Thus, this article will provide […]

U.S. Health officials order 100 million doses of Pfizer’s vaccine – does YIG see value?

Along with the NASDAQ, vaccine stocks have wrenched back the stock market remote control as the pandemic worsens. Today, it was Pfizer (NYSE: PFE) who stole the spotlight. U.S health officials have agreed to pay $1.95 billion for 100 million doses of  Pfizer and BioNTech coronavirus vaccine.  The news is causing the bulls to charge […]

Actinium Pharmaceuticals hits 150% gain over 2 months – here’s everything you need to know

Actinium Pharmaceuticals (NYSE:ATNM) has caught the attention of investors as the stock continues its path of strong bullish momentum. ATNM is likely to open at $0.56 according to pre-market movements, marking a 211% gain over the past 2 months. The Bio-Pharma works on the development of commercial therapies for bone marrow transplant and other adoptive cell […]

Astra Zeneca posts positive Phase I COVID-19 trial data yet investors sell – does YIG see potential?

Astra Zeneca (NYSE: AZN) had investors on the edge of their seats this morning in anticipation of COVID-19 data. AZN put investors at ease after their COVID-19 Phase I trial saw a positive immune response in patients. Most investors expected the stock to rocket off such news. However, investors instantly began to sell after the […]

Moderna COVID-19 vaccine success – here’s everything you need to know.

Moderna (NASDAQ:MRNA) alongside the US National Institutes of Health have made a historic breakthrough in the race for a viable COVID-19 vaccine. MRNA’s results showed all 45 patients from the Phase 1 trial saw an induced anti-body production. This anti-body production simply put helps bolster the individuals immune response to the virus. The markets are expected […]

Vaxart is up 60% on vaccine speculation – does YIG see potential?

Vaxart (NASDAQ:VXRT), like most COVID-19 stocks, is receiving a re-injection of investor confidence as the virus rages on. However, Vaxart is fairly new to the COVID-19 race, as they have not started any human trials yet. Some investors are straying away from Vaxart because of their late arrival and unlikelihood of creating a viable vaccine […]

NVAX receives $1.6 billion from Trump’s Operation Warp Speed, causing Novavax to cross $100 – should you invest?

Novavax (NASDAQ: NVAX) inched closer to the COVID-19 vaccine finish line after receiving $1.6 billion in government funding today. The bulls are now rally in large numbers behind the COVID-19 biotech. Especially in light of today’s announcement. However, many investors wonder how long it will be until the NVAX bulls have to rest? Because if […]